Synaptogenix Inc (SNPX) Quote

Doing well thanks. Not sure how to explain the bryostatin "group". I'm assuming the bryostain IP still falls into SNPX but looks like the company is focusing on other endeavors

been a long time,runn...hope all is well with you. I'm confused,is SNPX now a Crypto company? Is that " Bryostatin Platform Development Program" that Dr.Alkon is going to be heading still a part of this company? Anyway, sad for those of us who were here mainly for AD and Dr.Alkon.

Yeah I think I missed the PR.

I still follow the drug research and Alkon's diagnostic company but looks like nothing remains here that interests me I'm sad to say.

You are correct:

Cleveland Clinic

On February 23, 2022, the Company announced its collaboration with Cleveland Clinic to pursue possible treatments for Multiple Sclerosis (“MS”), and on July 19, 2023, the Company announced that it had entered into an agreement with Cleveland Clinic to conduct a Phase 1 trial of Bryostatin-1 in MS. Cleveland Clinic will manage the clinical trial’s implementation, including an IND submission to the FDA and patient enrollment. Cleveland Clinic has enrolled three subjects and has dosed two to - date, with the total planned enrollment in the MS Trial of 20 subjects. The total estimated costs associated with this collaboration are approximately $2.0 million. As of March 31, 2025, the Company has incurred expenses owed to Cleveland Clinic of approximately $528,000 of which $0 was expensed during the quarter ended March 31, 2025.

In December 2024, the Company announced via press release the termination of its agreement with the Cleveland Clinic due to the slow pace of enrollment in the Phase 1 clinical trial. The termination of the agreement was one of various actions authorized by the Board, designed to reduce cash burn rate.

I believe it was listed as abandoned in the most recent 10Q. Maybe I misread it. Sad if true

Looks like the study is still on - the clinicaltrials.gov listing was just updated in April and lists a 6/15/2026 primary completion date. Sanofi's tolebrutinib is currently at the FDA and will include a secondary progressive MS indication (Priority review Sept 28, 2025) and a couple other BTKi's and a CD40L mAb are in late stage for this indication as well. .

https://clinicaltrials.gov/study/NCT06190912?cond=Multiple%20Sclerosis&term=bryostatin&rank=1&tab=history&a=6&b=7#version-content-panel

Yeah, looks like alkon has resigned to become a consultant in an entity hoping to advance bryostatin research. He's not giving up his life's work yet. Not much left of the company for those who held on for AD reasons. I think the MS trial was discontinued due to low enrollment.

SNPX..............................................https://stockcharts.com/h-sc/ui?s=SNPX&p=W&b=5&g=0&id=p86431144783

Very newsy 8k. Particularly Crypto.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001571934/000110465925057640/tm2517474d1_8k.htm

Most recent MS independent bryostatin research out this month. Current trial is small and a long ways off but maybe will give hope to MS patients.
https://www.science.org/doi/10.1126/scitranslmed.adk3434

Thanks for this. It's a very well thought out theory based on a large number of patients in studies. I think it could play a role in the success or failure of Sava's drug later this year. Hoping for a positive outcome

A study shows that rising levels of brain protein Aß42, not the reduction of amyloid plaques, better explains the cognitive benefits of new Alzheimer’s drugs. This finding challenges the traditional focus on plaques in Alzheimer’s treatment.

A new study reveals that the rise in protein levels due to new Alzheimer’s drugs may explain the slowing of cognitive decline just as effectively as the reduction of amyloid plaques.

In a study that questions the effectiveness of newly approved monoclonal antibodies in reducing cognitive decline in Alzheimer’s patients by clearing amyloid, researchers from the University of Cincinnati discovered that an unintended rise in a critical brain protein’s levels correlates just as strongly with cognitive benefits.

Led by UC’s Alberto Espay, MD, the research was published in the journal Brain.

Study background
For decades, the prevailing theory in the field has stated that a protein made up of 42 amino acids called amyloid-beta 42 (Aß42) hardens into clumps called amyloid plaques, and those plaques damage the brain, causing Alzheimer’s disease.

Espay and team have hypothesized that normal, soluble Aß42 in the brain is crucial for neuron health and that the loss of Aß42, rather than the buildup of plaques, drives Alzheimer’s. This includes published research that suggests dementia occurs not when plaque levels are high but when Aß42 levels drop very low.

According to Espay’s research, the transformation of Aß42 into plaques appears to be the brain’s normal response to biological, metabolic, or infectious stress.

Alberto Espay
Alberto Espay, MD, MSc, professor of neurology at the UC College of Medicine and Director and Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders. Credit: Colleen Kelley/UC Brand + Creative
“Most of us will accrue amyloid plaques in our brains as we age, and yet very few of us with plaques go on to develop dementia,” said Espay, professor of neurology in the UC College of Medicine and director and endowed chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders at the UC Gardner Neuroscience Institute. “Yet the plaques remain the center of our attention in biomarker development and therapeutic strategies.”

Study details
Recently, several new monoclonal antibody medications designed to remove amyloid from the brain were approved after showing they lessened cognitive decline in clinical trials.

Espay and his colleagues noticed that these drugs unintentionally increased levels of Aß42.

“Amyloid plaques don’t cause Alzheimer’s, but if the brain makes too much of it while defending against infections, toxins, or biological changes, it can’t produce enough Aß42, causing its levels to drop below a critical threshold,” Espay explained. “That’s when dementia symptoms emerge.”

The team analyzed data from nearly 26,000 patients enrolled in 24 randomized clinical trials of these new antibody treatments, assessing cognitive impairment and differences in levels of Aß42 before and after treatment. They found that higher levels of Aß42 after treatment were independently associated with slower cognitive impairment and clinical decline.

“All stories have two sides — even the one we have told ourselves about how anti-amyloid treatments work: by lowering amyloid,” Espay said. “In fact, they also raise the levels of Aß42. Even if this is unintended, it is why there may be a benefit. Our study shows that we can predict changes in cognitive outcomes in anti-amyloid trials at least as well by the increases in Aß42 as by the decreases in amyloid.”

Espay said these findings fit well into his larger hypothesis about the root cause of Alzheimer’s, as increasing levels of Aß42 appear to improve cognition.

“If the problem with Alzheimer’s is the loss of the normal protein, then increasing it should be beneficial, and this study showed that it is,” he said. “The story makes sense: Increasing Aß42 levels to within the normal range is desirable.”

However, Espay believes these results also present a conundrum for clinicians because removing amyloid from the brain is toxic and may cause the brain to shrink faster after antibody treatment.

“Do we give patients an anti-protein treatment to increase their protein levels? I think the end, increasing Aß42, doesn’t justify the means, decreasing amyloid,” Espay said. Therapies that directly increase Aß42 levels without targeting amyloid are a focus of research for Espay and his group

SNPX under $4

Per 10q company finally gained synthetic bioequivalence. Of course only matters if they start additional trials

Thanks Doc. Yes more of an interest in the science at this point and sounds like even that's a long way off.

Here's a link to the trial on clinicaltrials.gov

https://clinicaltrials.gov/study/NCT06190912#participation-criteria

From inclusion criteria, it looks like this phase 1 will have a broad range of patients from no disability (EDSS 0) to using a walker (EDSS 7.0) and can have any form of MS (RRMS, SPMS, PPMS). This is open label with everyone receiving 14 doses over 26 weeks (similar dose as in the AD trials) and patients will continue on their existing MS medication. They can be on a stable dose of any MS med except teriflunomide (likely due to concerns of additive liver toxicity)

Cleveland clinic is one of the largest MS centers in the country and has access to a 7T research MRI, though all the MRI measures mentioned in the outcomes would be possible on a commercially available 3T (though not on 1.5T). However, Diffusion MRI and myelin water fraction will be more informative on a 7T. Though not on the list, I would expect them to also analyze paramagnetic rim lesions and grey matter lesion if the 7T is chosen.

If it is ever shown to have a benefit in MS, I suspect that bryostatin, based on MOA, would have more value in progressive MS than in earlier inflammatory/relapsing MS. With patients already on another DMT and with full range of disabilities in a small population for only 40 weeks, proving any clinical benefit will be very difficult in this study. Rather, I believe they are trying to prove a biologic effect and then will need to raise many millions to run a P2 for 2 years. From a science perspective this is very interesting but with a company having limited funds, the financial risk of investment is extremely high. A successful P1 trial still leads to a drug requiring many years of testing in a difficult indication

Wow SAVA getting killed today

Is this dog pile the next SAVA? Fingers crossed for the snake oil pumpers..

I do like the advanced MRI imaging for biomarkers. Could help in future AD studies hopefully. More science and less guess work.

A couple more months of conversion to dirt cheap shares theft and then the price should escalate up to something closer to reasonable market value.

For some context, the press release mentions $26.3 million in cash with a low burn rate and indications that are alive (MS in particular) while the current market cap is just over $5 million... These assholes have no shame with their blatant theft in the "regulated" public capital market...

It's good news. A bit delayed. Cleveland Clinic will run the trial and it will take a couple years. Doc would be a good one to comment as I believe this is his area of expertise. I would love to see an IND for FragileX but not sure of it's status if any. Seemingly telling that company hasn't mentioned AD in a long time.

Runn...your thoughts on today's news pls?
NEW YORK , June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) (" Synaptogenix " or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS).

NEW YORK , June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS).

Perpetual snake oil trash. Company will never amount to anything but robbing hopium holders.

Agreed

I don't think they are going to PR anything that would help the stock price. There is still several months of low priced stealing to occur...

Yeah I like COYA as well. NRSN put out additional results this morning showing a positive trend that hopefully allows a successful P3 trial in ALS as well.

The papers emphasize a common theme: Inflammation.
Another interesting theme is drug delivery using targeted Exosome carriers (T-Helpers).
$COYA is another biotech following a similar path but focusing on ALS.

Yeah there are several. Most of the work has been done by Johns Hopkins. Long ways off.
https://www.pnas.org/doi/full/10.1073/pnas.1719902115
https://pubs.rsc.org/en/content/articlelanding/2022/bm/d1bm01142a
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00625/full
https://www.sciencedirect.com/science/article/pii/S2451945620305249

Surprising.
Any more research papers backing this P1 trial?

According to the FDA clinical trials website the MS trial is now recruiting. It's a couple months later than the last site update but status went from "not recruiting" to "recruiting the last couple days. No idea if the company ever PRs this as the Cleveland Clinic is running the show. Maybe the upcoming quarterly (next week or two) will mention it. Long road until trial completes. We're talking 2026 most likely.

Not any time soon there isn't

Monster potential here ... SNPX

Doc, just wondering if you are continuing to follow Tiziana and if you had any thoughts regarding their progress. Best wishes.
https://www.globenewswire.com/news-release/2024/04/18/2865243/0/en/Tiziana-Life-Sciences-Announces-New-Quantitative-PET-Imaging-Data-on-Foralumab-at-the-Annual-Meeting-of-the-American-Academy-of-Neurology.html

Just like all the alternative AD drugs that have failed in AD unfortunately.

This shell was a trading vehicle, bryostatin failed multiple times. Insiders knew this. It's all linked in my sticky.

Executive Summary:

Neurotrope was created in a reverse merger in August 2013 by Adam Gottbetter and Michael Silverman. The Neurotrope promotion was delayed when Gottbetter was sent to prison for stock fraud in early 2015.
Gottbetter was released from prison in November 2016. Exactly ONE DAY LATER, NTRP raised approx. $25 million in a stock sale, run by Gottbetter's former partner Michael Silverman. NTRP price and volume took off ( nearly tripled in the following 100 days). The stock is now collapsing.
Gottbetter's former partner, Michael Silverman, was barred by FINRA after forging customer signatures ( link). He was also arrested and indicted as part of an illegal gambling ring run by the Luchese mafia crime family ( link).
NTRP's "drug" (bryostatin) has been evaluated for more than 48 years against AIDS, cancer and now Alzheimer's. Simply put: it always failed. Documents show that Blanchette Rockefeller Institute actually filed for bankruptcy on July 28, 2016 ( Link 1). BRNI was running the research on Bryostatin.
Just weeks after the BRNI bankruptcy filing, hedge fund manager Joshua Silverman supposedly left his fund Iroquois Capital to become Chairman of Neurotrope. Joshua Silverman and Iroquois are currently under SEC investigation for their role in an imploded stock promotion called MGT Capital which appears to be very similar to the Neurotrope promotion. Although Silverman says he left Iroquois, suddenly Neurotrope began using the same address as Iroquois.
Various parties involved in Neurotrope are using multiple arrangements to drain much of the cash from Neurotrope IMMEDIATELY after capital raises. They are making millions of dollars without any need for any successful drug - EVER.
Stock promoters behind Neurotrope are using alternate identities, but trace back to a New York IR firm called JV Public Relations NY which is linked to Neurotrope. Janet Vasquez, who runs JV Public Relations, was formerly the PR rep for Forcefield Energy (SunSi Energy), which was delisted due to fraud as its Chairman was arrested.
Below I will show that Sharon Di Stefano has written more than a dozen articles using the name "Small Cap Forecasting" or "SCF". But the phone number tied to SCF articles distributed though ACCESSWIRE actually belongs to JV Public Relations At least 10 (out of 15) of the companies covered by Di Stefano also happen to be tied to JV Public relations. All 10 of those stocks are also featured on an additional biotech stock promotion site which does not disclose compensation. THIS INCLUDES NEUROTROPE. INCIDENTALLY, IT ALSO INCLUDES TAPIMMUNE (TPIV).
Just like NTRP, Tapimmune is another stock where Joshua Silverman's Iroquois Capital holds 9.99%. Just like NTRP, Tapimmune received bullish coverage from Di Stefano. Just like NTRP, Di Stefano's bullish article was then disseminated by a paid press release tied to JV Public Relations. Just like NTRP, Tapimmune also used Michael Silverman's Katalyst Securities to raise money.
Despite the information contained in this report, Sharon Di Stefano claims that she doesn't know who Janet Vasquez or Jackie Rodriguez work for ( link). Truth is, they run JV Public Relations NY, the microcap IR firm in New York. The phone number listed as "media contact" for Di Stefano's Small Cap Forecasting happens to be the same as of JV Public Relations. Neurotrope has already come out with a public statement denying at it is not involved in any paid promotion behind its stock. Who is paying JV Public Relations NY?


My prior sticky is also linked, posted in August of 2020, this is the summary, historic quotes and evidence follow:


Neurotrope is a front for old money and connected folk. They are trying to commercialize a very OLD drug that has not been taken forward because it needs to be synthesized as the natural version is too rare. Most, if not all of the research on this drug has been paid for by the U.S. government.

Three years ago I stated my discomfort with the way this company came into being and was run:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=128690545

Shortly after this was posted the Pump and Dump I prophesied was realized and a great deal of retail money was taken out of the U.S. market, minimizing the risk of the founding stockholders.

Retail will continue to get the short end of the stick here to the bitter end. I will not invest in this company because I know how it ends... If the science is not successful the company goes broke and retail will be the bagholder. If it is successful read to the end of this post to find the outcome.

This drug is owned by old money "non profit" institutions. These are the two most prominent in the story:

Rockefeller Neuroscience Institute
https://directory.hsc.wvu.edu/Department/2192

Woods Hole Oceanographic Institution
www.whoi.edu

The initial investors have been selling stock to recoup their initial cost of funding the company on price spikes and replenishing it with warrants.

I am not convinced that treating Alzheimer's is the primary goal of Neurotrope. It is also not clear that people who buy stock in NTRP will be the primary beneficiaries if the company is successful. I suspect it will be the founding stockholders who have probably already made most of their "investment" back by selling at higher prices.

I am also not sure if there is solid protection for the IP as with proof of concept someone might design a new synthetic chemical that could do it all better. They have patents but I don't know how enforceable they would be against a newly designed chemical.

This paragraph is updated from the previous sticky:

I think Anavex may draw the ire of NTRP proponents because 2-73 creates cellular homeostasis which is both neuroprotective and allows neurogenesis to take place. Blarcamesine or 2-73 is in trials for Alzheimer's, Parkinson's dementia, and is both neuroprotective and restorative. It is more economical than bryostatin could ever be and may get provisional approval from the Australian TGA within a year.


... and then there's 3-71.





https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157967774

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics
https://ir.synaptogen.com/news-releases/?qmodStoryID=7600649204374859

Totally understand. Hoping for the best!

I had kept few for ol' times sakes(that now got slashed by 1/25- post RS), so have only a piddly few left. If something good comes of this, will celebrate not in terms of $$ but for the dreaded disease.As long as Dr.Alkon is alive here I will hold, but like you no big hopes for me either. Good luck on everything runn

If I owned it, I would be looking for a possible MS trial or something similar to create a nice bump on this low float. There will be no trial readouts in 2024 or 2025 that I can see. I hope for the best with this drug, but it hasn't been investable since the trial failed well over a year ago. Jmho

Not been around for a bit, seeing that our SNPX has had an RS recently.Nice action since, maybe we dare to get our hopes up again runn,lol?

SNPX BIG POST SPLIT PUSH

Dog pile heading to the bargain bin in short order. Book it. The masters of charletry.

SNPX...HERE WE GO

SNPX....HEATING UP

Low floater now. Haven't owned in awhile. Could have a move if they ever announce the MS trial I suppose

SNPX...FREASH OFF THE SPLIT...

SNPX 10Q due 3/27

I noticed the SAVA results today. It’s a small play for me.

I’m still invested in some AD plays including Synaptogenix.

Some reasonably good results on Sava today so at least a few alternative plays still out there. Hoping bryostatin gets another shot on moderate AD as it seems to be the only one with a shot at halting the disease. Looks like the MS trial kicks off this month. I'm not in any of the AD plays at the moment in full disclosure.